BMEA Biomea Fusion, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 5, 2026
$1.27
· % 处于52周区间
· 高于低点
· 至高点
$0.8752周低点
$2.9952周高点
市值 (MRQ)
$92M
P/E
-1.1
EPS
$-1.18
BMEA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$1.27
市值 (MRQ)
$92M
P/E
-1.1
EPS
$-1.18
ROE
-216.6%
52周区间
$1–$3
BMEA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-1.182020-12-31 → 2025-12-31
自由现金流·2021-12-31 → 2024-12-31
净利率-3326.0%2025-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | BMEA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -1.15年均值 ≈-2.7 | ≈-2.7 | · | · | |
| 市净率 (MRQ) | 7.65年均值 ≈2.5 | ≈2.5 | 1.7 | 估值过高 | |
| Price / Cash Flow (市现率) | -1.35年均值 ≈-3.6 | ≈-3.6 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 3.15年均值 ≈2.5 | ≈2.5 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | BMEA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Operating Margin (营业利润率) | -4494.7% | · | -2375.5% | 低于平均水平 | |
| EBITDA Margin (息税折旧摊销前利润率) | -4494.7% | · | -2375.5% | 低于平均水平 | |
| Net Profit Margin (净利润率) | -3326.0% | · | -1689.0% | 低于平均水平 | |
| ROA | -89.2%5年均值 ≈-69.0% | ≈-69.0% | -31.6% | 弱 | |
| ROE | -216.6%5年均值 ≈-117.6% | ≈-117.6% | -61.2% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | BMEA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 3.55年均值 ≈12.1 | ≈12.1 | 4.1 | 低于平均水平 | |
| Quick Ratio (速动比率) | 5.05年均值 ≈11.8 | ≈11.8 | 3.3 | 持平 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | BMEA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | -67.1% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | BMEA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.0 | · | 0.0 | 顶尖 |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
38.6%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 3, 2026 | $-0.12 | $-0.23 | 47.4% |
| 2026年3月31日 | $-0.17 | $-0.24 | 29.8% | |
| 2025年12月31日 | $0.27 | $-0.26 | 205.3% | |
| 2025年9月30日 | $-0.27 | $-0.26 | -3.5% | |
| 2025年6月30日 | $-0.51 | $-0.54 | 5.8% | |
| 2025年3月31日 | $-0.80 | $-0.62 | -28.2% | |
| 2024年12月31日 | $-0.81 | $-0.94 | 13.8% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $62M | $118M | $103M | $63M | $28M | $4M | |
| SG&A Expense | $19M | $26M | $24M | $21M | $14M | $2M | |
| Operating Expenses | $84M | $144M | $126M | $84M | $42M | $5M | |
| Operating Income | $-84M | $-144M | $-126M | $-84M | $-42M | $-5M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-62M | $-138M | $-117M | $-82M | $-42M | $-5M | |
| EPS (Basic) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 | $-0.51 | |
| EPS (Diluted) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 | $-0.51 | |
| Shares (Basic) | 52,228,068 | 36,105,671 | 34,106,923 | 29,271,777 | 23,858,552 | 10,532,942 | |
| Shares (Diluted) | 52,228,068 | 36,105,671 | 34,106,923 | 29,271,777 | 23,858,552 | 10,532,942 | |
| EBITDA | $-84M | $-144M | $-126M | $-84M | $-42M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $56M | $58M | $177M | $112M | $146M | $62M | |
| Short-term Investments | · | · | · | $1M | $28M | · | |
| Receivables | · | · | · | · | · | $16.0K | |
| Prepaid Expense | $2M | $10M | $2M | $5M | $3M | $528.0K | |
| Other Current Assets | · | · | · | · | · | $29.0K | |
| Current Assets | $58M | $68M | $179M | $118M | $177M | $62M | |
| PP&E (Net) | $153.0K | $4M | $5M | $6M | $3M | $81.0K | |
| PP&E (Gross) | $1M | $8M | $8M | $7M | $3M | $89.0K | |
| Accum. Depreciation | $1M | $4M | $2M | $916.0K | $257.0K | $8.0K | |
| Other Non-current Assets | $0 | $619.0K | $6M | $3M | $1M | $12.0K | |
| Total Assets | $59M | $80M | $200M | $129M | $186M | $63M | |
| Accounts Payable | $3M | $13M | $7M | $7M | $1M | $727.0K | |
| Accrued Liabilities | · | · | · | · | · | $633.0K | |
| Current Liabilities | $11M | $22M | $23M | $19M | $5M | $2M | |
| Capital Leases | $128.0K | $7M | $8M | $2M | $2M | · | |
| Total Liabilities | $29M | $28M | $31M | $21M | $7M | $2M | |
| Common Stock | $7.0K | $4.0K | $4.0K | $3.0K | $3.0K | $1.0K | |
| Paid-in Capital | $479M | $439M | $418M | $240M | $229M | $13M | |
| Retained Earnings | $-449M | $-387M | $-249M | $-132M | $-50M | $-8M | |
| AOCI | · | · | · | $-1.0K | $-10.0K | · | |
| Stockholders' Equity | $30M | $52M | $169M | $109M | $179M | $5M | |
| Liabilities + Equity | $59M | $80M | $200M | $129M | $186M | $63M | |
| Shares Outstanding | 72,299,440 | 36,310,713 | 35,866,610 | 29,561,554 | 29,115,421 | 11,953,107 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $19M | $14M | $10M | $6M | $322.0K | |
| Operating Cash Flow | $-70M | $-120M | $-97M | $-62M | $-35M | $-4M | |
| CapEx | · | $362.0K | $3M | $1M | $3M | $51.0K | |
| Investing Cash Flow | · | $-362.0K | $-2M | $27M | $-33M | $-51.0K | |
| Stock Issued | $5M | · | $162M | · | · | $10M | |
| Net Stock Activity | $5M | · | $162M | · | · | · | |
| Financing Cash Flow | $68M | $2M | $164M | $1M | $153M | $66M | |
| Net Change in Cash | $-2M | $-119M | $65M | $-34M | $84M | $61M | |
| Free Cash Flow | · | $-120M | $-100M | $-63M | $-39M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -4494.7% | · | · | · | · | · | |
| Net Margin | -3326.0% | · | · | · | · | · | |
| EBITDA Margin | -4494.7% | · | · | · | · | · | |
| ROA | -89.2% | -98.9% | -71.2% | -51.9% | -33.5% | · | |
| ROE | -216.6% | -217.1% | -63.6% | -68.4% | -22.5% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 3.2 | 7.8 | 6.2 | 38.1 | · | |
| Quick Ratio | 5.0 | 2.7 | 7.7 | 5.9 | 37.4 | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $1.42 | $4.72 | $3.67 | $6.14 | · | |
| Revenue / Share | $0.04 | · | · | · | · | · | |
| Cash Flow / Share | $-1.35 | $-3.32 | $-2.83 | $-2.13 | · | · | |
| Cash / Share | $0.77 | $1.60 | $4.93 | $3.79 | $5.01 | · | |
| EPS (TTM) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -67.1% | -36.4% | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-62M | $-138M | $-117M | $-82M | $-42M | · | |
| Market Cap | $90M | $141M | $521M | $249M | $217M | · | |
| P/E | -1.1 | -1.0 | -4.2 | -3.0 | -4.3 | · | |
| P/B | 3.0 | 2.7 | 3.1 | 2.3 | 1.2 | · | |
| P / Tangible Book | 3.0 | 2.7 | 3.1 | 2.3 | 1.2 | · | |
| P / Cash Flow | -1.3 | -1.2 | -5.4 | -4.0 | -6.1 | · | |
| P / FCF | · | -1.2 | -5.2 | -3.9 | -5.6 | · | |
| Earnings Yield | -95.2% | -98.7% | -23.7% | -33.2% | -23.4% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $165M | |
| R&D Expense | $9M | $9M | $8M | $14M | $17M | $23M | $25M | $27M | $32M | $34M | $31M | $25M | $22M | $24M | $21M | $18M | |
| SG&A Expense | $4M | $4M | $4M | $4M | $5M | $7M | $5M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $5M | |
| Operating Expenses | $13M | $13M | $12M | $21M | $21M | $30M | $30M | $34M | $39M | $41M | $37M | $31M | $28M | $30M | $26M | $23M | |
| Operating Income | $-13M | $-13M | $-12M | $-21M | $-21M | $-30M | $-30M | $-34M | $-39M | $-41M | $-37M | $-31M | $-28M | $-30M | $-26M | $-23M | |
| Net Income | $-8M | $-12M | $5M | $-16M | $-21M | $-29M | $-29M | $-33M | $-37M | $-39M | $-35M | $-28M | $-25M | $-29M | $-25M | $-23M | |
| EPS (Basic) | $-0.12 | $-0.17 | $0.40 | $-0.27 | $-0.51 | $-0.80 | $-0.80 | $-0.91 | $-1.03 | $-1.09 | $-0.96 | $-0.80 | $-0.70 | $-0.98 | $-0.87 | $-0.78 | |
| EPS (Diluted) | $-0.12 | $-0.17 | $0.40 | $-0.27 | $-0.51 | $-0.80 | $-0.80 | $-0.91 | $-1.03 | $-1.09 | $-0.96 | $-0.80 | $-0.70 | $-0.98 | $-0.87 | $-0.78 | |
| Shares (Basic) | 72,360,235 | 72,299,440 | · | 59,848,325 | 40,630,403 | 36,627,148 | 36,265,001 | 36,220,736 | 36,043,561 | 35,890,370 | 35,754,165 | 35,653,988 | 35,348,293 | 29,586,468 | 29,441,596 | 29,319,042 | |
| Shares (Diluted) | 72,360,235 | 72,299,440 | · | 59,848,325 | 40,630,403 | 36,627,148 | 36,265,001 | 36,220,736 | 36,043,561 | 35,890,370 | 35,754,165 | 35,653,988 | 35,348,293 | 29,586,468 | 29,441,596 | 29,319,042 | |
| EBITDA | $-13M | $-13M | · | $-21M | $-21M | $-30M | · | $-34M | $-39M | $-41M | · | $-31M | $-28M | $-30M | · | $-23M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $35M | $45M | $56M | $47M | $56M | $36M | $58M | $88M | $113M | $145M | $177M | $199M | $223M | $86M | $112M | $132M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Prepaid Expense | $1M | $1M | $2M | $3M | $8M | $9M | $10M | $6M | $3M | $3M | · | $3M | $3M | $3M | · | $5M | |
| Current Assets | $36M | $46M | $58M | $49M | $65M | $45M | $68M | $94M | $116M | $148M | · | $203M | $226M | $89M | · | $139M | |
| PP&E (Net) | $47.0K | $67.0K | $153.0K | $200.0K | $3M | $3M | $4M | $4M | $4M | $5M | · | $6M | $6M | $6M | · | $3M | |
| PP&E (Gross) | · | $668.0K | $1M | $1M | $8M | $8M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | $4M | |
| Accum. Depreciation | · | $601.0K | $1M | $962.0K | $5M | $5M | $4M | $4M | $3M | $3M | · | $2M | $2M | $1M | · | $733.0K | |
| Other Non-current Assets | $398.0K | · | $0 | $0 | $4.0K | $617.0K | $619.0K | $5M | $7M | $7M | · | $5M | $4M | $4M | · | · | |
| Total Assets | $37M | $46M | $59M | $55M | $73M | $55M | $80M | $110M | $136M | $168M | · | $225M | $249M | $113M | · | $145M | |
| Accounts Payable | $3M | $5M | $3M | $6M | $8M | $8M | $13M | $9M | $6M | $5M | · | $3M | $4M | $5M | · | $2M | |
| Current Liabilities | $10M | $9M | $11M | $16M | $18M | $20M | $22M | $28M | $25M | $25M | · | $16M | $14M | $19M | · | $13M | |
| Capital Leases | $0 | $0 | $128.0K | $6M | $6M | $7M | $7M | $7M | $7M | $8M | · | $9M | $10M | $11M | · | $2M | |
| Total Liabilities | $25M | $28M | $29M | $40M | $46M | $26M | $28M | $34M | $32M | $33M | · | $25M | $24M | $30M | · | $14M | |
| Common Stock | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | · | $4.0K | $4.0K | $3.0K | · | $3.0K | |
| Paid-in Capital | $482M | $480M | $479M | $469M | $465M | $445M | $439M | $434M | $429M | $423M | · | $414M | $410M | $244M | · | $237M | |
| Retained Earnings | $-470M | $-461M | $-449M | $-454M | $-437M | $-417M | $-387M | $-358M | $-325M | $-288M | · | $-214M | $-186M | $-161M | · | $-106M | |
| AOCI | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Stockholders' Equity | $12M | $19M | $30M | $16M | $28M | $29M | $52M | $76M | $104M | $135M | $169M | $200M | $224M | $83M | $109M | $131M | |
| Liabilities + Equity | $37M | $46M | $59M | $55M | $73M | $55M | $80M | $110M | $136M | $168M | · | $225M | $249M | $113M | · | $145M | |
| Shares Outstanding | 72,483,852 | 72,299,440 | 72,299,440 | 59,508,518 | 58,127,256 | 37,572,250 | 36,310,713 | 36,238,280 | 36,184,485 | 35,933,586 | · | 35,698,847 | 35,630,276 | 29,651,134 | · | 29,388,753 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | |
| Operating Cash Flow | $-10M | $-12M | $-14M | $-12M | $-19M | $-26M | $-30M | $-25M | $-33M | $-32M | $-23M | $-24M | $-26M | $-24M | $-20M | $-17M | |
| CapEx | · | · | · | $0 | $0 | $0 | $82.0K | $186.0K | $59.0K | $35.0K | $8.0K | $39.0K | $417.0K | $3M | $712.0K | $-50.0K | |
| Investing Cash Flow | $0 | $550.0K | · | $0 | $0 | $0 | $-82.0K | $-186.0K | $-59.0K | $-35.0K | $-8.0K | $-39.0K | $-417.0K | $-2M | $-701.0K | $225.0K | |
| Stock Issued | · | · | $-124.0K | $0 | $2M | $3M | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | · | · | $3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | · | · | $23M | $2M | $40M | $3M | $413.0K | $69.0K | $1M | $116.0K | $622.0K | $138.0K | $163M | $201.0K | $490.0K | $400.0K | |
| Net Change in Cash | $-10M | $-11M | $9M | $-10M | $20M | $-22M | $-30M | $-25M | $-32M | $-32M | $-22M | $-24M | $137M | $-26M | $-20M | $-16M | |
| Free Cash Flow | · | · | · | · | · | $-26M | · | · | · | $-32M | · | · | · | $-27M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4001.9% | -2970.7% | · | -473.1% | -3969.4% | -6602.7% | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -2610.7% | -2887.2% | · | -373.1% | -3869.4% | -6502.7% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -4001.9% | -2970.7% | · | -473.1% | -3969.4% | -6602.7% | · | · | · | · | · | · | · | · | · | · | |
| ROA | -15.1% | -24.5% | · | -19.8% | -19.8% | -26.2% | · | -19.5% | -19.4% | -27.8% | · | -15.4% | -12.1% | -20.2% | · | -13.3% | |
| ROE | -42.0% | -52.3% | · | -35.8% | -31.6% | -35.7% | · | -23.8% | -22.7% | -35.8% | · | -17.2% | -13.3% | -23.4% | · | -14.2% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 5.0 | · | 3.2 | 3.7 | 2.3 | · | 3.4 | 4.6 | 5.8 | · | 12.5 | 15.7 | 4.7 | · | 11.0 | |
| Quick Ratio | 3.3 | 4.8 | · | 3.0 | 3.2 | 1.8 | · | 3.2 | 4.5 | 5.7 | · | 12.3 | 15.5 | 4.6 | · | 10.6 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.17 | $0.26 | · | $0.26 | $0.47 | $0.76 | · | $2.10 | $2.87 | $3.77 | · | $5.59 | $6.30 | $2.80 | · | $4.45 | |
| Revenue / Share | $0.00 | $0.01 | · | $0.07 | $0.01 | $0.01 | · | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.16 | · | · | · | $-0.70 | · | · | · | $-0.89 | · | · | · | $-0.81 | · | · | |
| Cash / Share | $0.48 | $0.62 | · | $0.78 | $0.97 | $0.95 | · | $2.43 | $3.13 | $4.03 | · | $5.58 | $6.26 | $2.91 | · | $4.50 | |
| EPS (TTM) | $-0.16 | $-0.55 | · | $-2.38 | $-3.02 | $-3.54 | · | $-3.99 | $-3.88 | $-3.55 | · | $-3.35 | $-3.33 | $-3.22 | · | $-2.46 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-33M | $-45M | · | $-96M | $-112M | $-129M | · | $-144M | $-140M | $-127M | · | $-108M | $-102M | $-95M | · | $-71M | |
| Market Cap | $107M | $111M | · | $120M | $105M | $80M | · | $366M | $163M | $537M | · | $491M | $782M | $919M | · | $287M | |
| P/E | -9.2 | -2.8 | · | -0.8 | -0.6 | -0.6 | · | -2.5 | -1.2 | -4.2 | · | -4.1 | -6.6 | -9.6 | · | -4.0 | |
| P/B | 8.8 | 5.9 | · | 7.7 | 3.8 | 2.8 | · | 4.8 | 1.6 | 4.0 | · | 2.5 | 3.5 | 11.1 | · | 2.2 | |
| P / Tangible Book | 8.8 | 5.9 | · | 7.7 | 3.8 | 2.8 | · | 4.8 | 1.6 | 4.0 | · | 2.5 | 3.5 | 11.1 | · | 2.2 | |
| P / Cash Flow | · | -9.5 | · | · | · | -3.1 | · | · | · | -16.8 | · | · | · | -38.2 | · | · | |
| Earnings Yield | -10.9% | -35.9% | · | -117.8% | -167.8% | -166.2% | · | -39.5% | -86.2% | -23.8% | · | -24.3% | -15.2% | -10.4% | · | -25.1% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 营业利润率 % | -4494.7% | · | · | · | · |
| 净收入 | $-62M | $-138M | $-117M | $-82M | $-42M |
| 稀释后每股收益 (EPS) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 5.2 | 3.2 | 7.8 | 6.2 | 38.1 |
| 速动比率 | 5.0 | 2.7 | 7.7 | 5.9 | 37.4 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | · | $-120M | $-100M | $-63M | $-39M |
机构持有人 (13F) 73 家申报者 · $41.7M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
73
持有价值
$41.7M
新仓位
8
已退出持仓
14
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 8 (-9 与上一季度对比) | 14 (+6 与上一季度对比) | 25 (+6 与上一季度对比) | 11 (-3 与上一季度对比) | +1.3M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| FMR LLC | $12957970 | 8814946 | 31.04% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4159993 | 2829927 | 9.97% | 股份 |
| VANGUARD GROUP INC | $3680371 | 2968041 | 8.82% | 股份 |
| MARSHALL WACE, LLP | $3013208 | 2049802 | 7.22% | 股份 |
| Aisling Capital Management LP | $3011673 | 2048757 | 7.22% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $2139547 | 1455474 | 5.13% | 股份 |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | $1063069 | 723176 | 2.55% | 股份 |
| BlackRock, Inc. | $1051704 | 715445 | 2.52% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $1042477 | 708854 | 2.50% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $900720 | 612735 | 2.16% | 股份 |
| Mariner, LLC | $874247 | 594726 | 2.09% | 股份 |
| JANE STREET GROUP, LLC | $673685 | 458289 | 1.61% | 股份 |
| UBS Group AG | $653750 | 444728 | 1.57% | 股份 |
| XTX Topco Ltd | $598112 | 406879 | 1.43% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $585795 | 398500 | 1.40% | 买入期权 |
| TWO SIGMA INVESTMENTS, LP | $565155 | 384459 | 1.35% | 股份 |
| MORGAN STANLEY | $539521 | 367021 | 1.29% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $497367 | 338345 | 1.19% | 股份 |
| MAI Capital Management | $424977 | 289100 | 1.02% | 股份 |
| STATE STREET CORP | $378253 | 257315 | 0.91% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $317226 | 215800 | 0.76% | 卖出期权 |
| CITADEL ADVISORS LLC | $262101 | 178300 | 0.63% | 买入期权 |
| LMR Partners LLP | $261000 | 200000 | 0.63% | 股份 |
| NORTHERN TRUST CORP | $188933 | 128526 | 0.45% | 股份 |
| JANE STREET GROUP, LLC | $180810 | 123000 | 0.43% | 买入期权 |
| Headlands Technologies LLC | $163683 | 111349 | 0.39% | 股份 |
| Marex Group Ltd | $147000 | 100000 | 0.35% | 股份 |
| GOLDMAN SACHS GROUP INC | $137822 | 93757 | 0.33% | 股份 |
| TWO SIGMA ADVISERS, LP | $131192 | 105800 | 0.31% | 股份 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $124362 | 84600 | 0.30% | 股份 |
| Jain Global LLC | $111276 | 75698 | 0.27% | 股份 |
| GRIFFIN ASSET MANAGEMENT, INC. | $87906 | 59800 | 0.21% | 股份 |
| SUPERSTRING CAPITAL MANAGEMENT LP | $85306 | 250000 | 0.20% | 股份 |
| Graham Capital Management, L.P. | $78579 | 53455 | 0.19% | 股份 |
| CITADEL ADVISORS LLC | $66027 | 44916 | 0.16% | 股份 |
| ADAR1 Capital Management, LLC | $63827 | 43420 | 0.15% | 股份 |
| Rathbones Group PLC | $54390 | 37000 | 0.13% | 股份 |
| Vanguard Global Advisers, LLC | $50900 | 34626 | 0.12% | 股份 |
| Point72 Asset Management, L.P. | $48204 | 32792 | 0.12% | 股份 |
| WOLVERINE TRADING, LLC | $36462 | 17700 | 0.09% | 买入期权 |
| PNC Financial Services Group, Inc. | $35280 | 24000 | 0.08% | 股份 |
| Bank of New York Mellon Corp | $23184 | 15771 | 0.06% | 股份 |
| CFS Investment Advisory Services, LLC | $22303 | 15818 | 0.05% | 股份 |
| BIRCH FINANCIAL GROUP, LLC | $20580 | 14000 | 0.05% | 股份 |
| TWO SIGMA SECURITIES, LLC | $20545 | 13976 | 0.05% | 股份 |
| Point72 Asia (Singapore) Pte. Ltd. | $20259 | 10029 | 0.05% | 股份 |
| CITADEL ADVISORS LLC | $19404 | 13200 | 0.05% | 卖出期权 |
| Qube Research & Technologies Ltd | $18668 | 12699 | 0.04% | 股份 |
| NewEdge Advisors, LLC | $17640 | 12000 | 0.04% | 股份 |
| Creative Planning | $17640 | 12000 | 0.04% | 股份 |
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP, Chen Bihua ×5 申报 | 2025年10月24日 | 1.53% | 修订 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 12 位内幕人士 · 5 位高管 · 8 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Michael J.M. Hitchcock | Interim CEO | 2026年4月1日 A | 115000 | 1 | 0 | $99000 |
| Thomas Andrew Butler | Chief Executive Officer | 2024年1月17日 A | 228470 | 0 | 0 | $0 |
| Franco Valle | Chief Financial Officer | 2024年11月30日 A | 42995 | 0 | 0 | $0 |
| Rainer M Erdtmann | President, Chief Operating Officer, Principal Financial Officer, and Principal Accounting Officer | 2026年4月1日 A | 723027 | 3 | 0 | $97400 |
| Juan Pablo Frias | Chief Medical Officer | 2024年5月31日 A | 349 | 0 | 0 | $0 |
| Julianne Averill | 董事 | 2026年6月10日 A | · | 0 | 0 | $0 |
| Sumita Ray | 董事 | 2026年6月10日 A | · | 0 | 0 | $0 |
| Elizabeth Faust | 董事 | 2026年6月10日 A | · | 0 | 0 | $0 |
| Eric Aguiar | 董事 | 2026年6月10日 A | · | 0 | 0 | $0 |
| Sotirios Stergiopoulos | 董事 | 2021年9月17日 P | 4400000 | 0 | 0 | $0 |
| A2A Pharmaceuticals, Inc. | 10% 所有者 | 2023年6月1日 S | 3500000 | 0 | 0 | $0 |
| Biomea Health, LLC | 10% 所有者 | 2022年6月1日 J | 0 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 3 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
BMEA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 13 位分析师
买入
中位数目标
$7.00
+451.2%
5 38.5%
强烈买入
6 46.2%
买入
1 7.7%
持有
1 7.7%
卖出
0 0.0%
强烈卖出
12个月价格目标
6 位分析师 · 2026-09-29平均目标 $6.50 +411.8%
← 低于所有目标
当前价格 $1.27
最低$4.00
平均值$6.50
最高$9.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| BMEA | $90M | -1.1 | -67.1% | -3326.0% | -216.6% | · |
| OKUR | · | -0.7 | · | -1733.7% | -88.6% | · |
| ANIX | $136M | -12.1 | 0.00% | · | -62.2% | · |
| EQ | $95M | -4.0 | 13.9% | · | -133.1% | · |
| CRDF | $192M | -4.1 | -13.2% | -7732.0% | -88.2% | · |
| CTOR | $170M | -6.0 | · | · | -61.5% | · |
| CNXU | · | · | · | · | · | · |
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | · |
| MNOV | $64M | -5.5 | · | -2928.8% | -27.1% | · |
| ICCC | · | -51.2 | 4.3% | · | · | · |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 5, 2026 申报